Notable insider buying and selling activity across public companies.
Tracking and analysis of reported insider transactions, including executive and director buying or selling. Insider activity can offer insight into internal confidence, valuation perceptions, and potential inflection points.
12,100 total articles
Workday Inc. Chief Financial Officer Zane Rowe sold 5,990 shares of Class A common stock on April 7, 2026, for roughly $769,314 in multiple trades executed under a Rule 10b5-1 plan. He also sold 9,140 shares on April 5, 2026, to cover tax liabilities from restricted stock unit vesting. The company recently reported Q4 FY2026 results that met revenu…
David A. Duffield, a roughly 10% owner of Workday, sold about $13.9 million of Class A common stock on April 6, 2026, while converting a substantial block of Class B shares into Class A. The insider activity coincides with recent quarterly results that met revenue guidance and beat earnings, analyst price-target adjustments, and corporate moves inc…
Lipocine Inc. director John W. Higuchi purchased 40,000 shares on April 7, 2026, paying $2.03 per share for a total of $81,199, according to a Form 4 filing. The stock is trading close to its 52-week low after a steep pullback, while the company disclosed that its postpartum depression candidate LPCN 1154 did not meet the Phase 3 primary endpoint i…
Travere Therapeutics director Baynes Roy D. sold 10,000 shares on April 6, 2026, at $33.00 per share while exercising options to acquire 10,000 shares at $26.52. The company faces a three-month FDA review extension for its Filspari sNDA, moving the PDUFA date to April 13, 2026, and Stifel maintains a Hold rating with a $31.00 price target.
Greg E. Jansen, Perdoceo Education's senior vice president and general counsel, sold 30,158 shares on April 6, 2026, for $38.00 per share, generating proceeds of $1.14 million. The transaction was executed through a Rule 10b5-1 trading plan adopted last November. Separately, the company's compensation committee approved the 2026 Annual Incentive Pl…
Cathay General Bancorp President and CEO Liu Chang sold 4,836 shares on April 6, 2026 through a pre-set Rule 10b5-1 trading plan, generating $243,505. The bank recently posted Q4 fiscal 2025 results that beat estimates and declared a quarterly dividend, while also announcing a CFO retirement and named successor.
Terilyn J. Monroe, Chief People Officer at Guardant Health, executed a sale of 3,832 common shares on April 6, 2026, for $92.68 per share, generating proceeds of roughly $355,149. The transaction occurred while Guardant Health shares traded near $93.32 after a one-year gain of 123%. Following the sale, Monroe retains direct ownership of 20,990 shar…
Gladstone Commercial Corp. Executive Vice President Ryan Stuart Carter purchased 100 shares of company common stock on April 1, 2026, for $11.48 per share, a $1,148 transaction that brings his direct holdings to 4,400 shares. The transaction comes as the REIT trades near an InvestingPro fair value estimate and offers a double-digit dividend yield. …
Security National Financial Corp director Gilbert A. Fuller disposed of 10,000 shares of Class A common stock on April 7, 2026, for $9.45 a share, a transaction valued at $94,500. The sale took place near the quoted market price and follows previously granted restricted stock units that will vest through the end of 2026.
A Form 4 filing shows director Nauman Clynton R. bought 10,000 shares of Contango Silver & Gold Inc. (EXCHANGE:CTGO) on April 1, 2026, at $18.56 per share, a $185,600 transaction that brings his direct holdings to 24,550 shares. Separately, Contango Ore Inc. posted a significant fourth-quarter 2025 earnings miss with EPS of -$4.22 versus a projecte…
Luke Alverson, senior vice president, general counsel and secretary of CSW Industrials Inc. (NASDAQ: CSWI), sold 1,007 shares on April 7, 2026 for $267,972 and exercised performance rights that produced additional share issuances. The company also reported third-quarter fiscal 2025 results that fell short of analyst expectations, with an adjusted E…
Remitly Global director Joshua Hug sold 1,430 shares on April 6, 2026, for $15.99 apiece, totaling $22,865. The transaction was carried out under a Rule 10b5-1 trading plan adopted December 11, 2025. Following the sale, Hug directly holds 3,574,303 shares and indirectly controls 300,000 shares through a family trust. The move coincides with Remitly…
Lamb Weston director Peter J. Bensen purchased 5,000 shares on April 6, 2026, valued at $197,225, bringing his direct holdings to 20,492.7 shares and indirect holdings via a revocable trust to 17,204 shares. The stock trades near its 52-week low following a significant six-month decline. The company has reported stronger-than-expected quarterly EBI…
John Uczekaj, President and COO of AIRO Group Holdings, filed a Form 4/A disclosing the sale of 144 shares on April 6, 2026. The sale, executed at a weighted average price of $8.8364, generated $1,272 and was used to meet tax-withholding obligations tied to vested restricted stock units. AIRO reported fourth-quarter 2025 revenue of $48.3 million, a…
Viant Technology Inc.'s Chief Financial Officer, Larry Madden, sold 7,297 shares of Class A common stock on April 6, 2026, under a 10b5-1 plan, realizing $82,517. The transaction occurred at a weighted average price of $11.3084 within a $11.165 to $11.505 range. The stock has risen 33% over six months but trades below the sale price at $10.94. The …
Helen Torley, President and CEO of Halozyme Therapeutics (NASDAQ: HALO), sold 10,000 shares on April 6, 2026 under a pre-set 10b5-1 plan for $634,981 and simultaneously exercised options to acquire 10,000 shares at $12.07. The company reported robust revenue gains but a non-GAAP diluted loss per share driven by acquisition-related write-offs; analy…
Hims & Hers Health, Inc. Chief Financial Officer Oluyemi Okupe completed an exercise of options and an associated sale of Class A shares on April 6, 2026. The transactions — executed under a pre-arranged Rule 10b5-1 trading plan — coincided with company news of a partnership with Novo Nordisk to offer FDA-approved GLP-1 medications and with a notab…
Ulta Beauty director George R. Mrkonic Jr. sold 452 shares of the company's common stock on April 7, 2026, for a weighted average price of $539.29, totaling $243,759. The sale, carried out by the company's chief legal officer under a power of attorney, leaves Mrkonic with 2,383 shares. Analysts continue to rate the stock favorably overall but offer…
Luke Stevens Putman, senior vice president and general counsel of Black Stone Minerals, L.P., sold 29,386 common units on April 6, 2026, generating proceeds of $424,677. The transaction occurred as the partnership's shares traded close to a 52-week high, after a fourth-quarter earnings and revenue beat and amid an InvestingPro assessment that the s…
On April 7, 2026, Mastin Celeste Beeks, president and CEO of Fuller H B Co (NYSE: FUL), bought 5,170 shares for $57.08 each, a $295,103 transaction that raised his indirectly held stake. The purchase occurred while the stock traded near $57.78, close to its 52-week low, and follows a quarterly earnings report that missed analysts' expectations.
Intellicheck CEO Bryan Lewis sold 10,000 shares on April 6, 2026, at $7.5254 under a Rule 10b5-1 plan and transferred 80,000 shares to The Lewis Family Revocable Living Trust. The stock is trading near its 52-week high after a 221% year-over-year gain, and the company reported Q4 2025 results that exceeded expectations on both earnings and revenue.
Amanda J. Thompson, Gap Inc.'s Chief People Officer, sold 25,000 shares of common stock on April 6, 2026, for a weighted average price of $25.1354, generating roughly $628,385. Following the transactions she retains direct ownership of 86,228 shares. The stock is trading at $24.73 versus an InvestingPro Fair Value of $30.08. Separately, Gap reporte…
Lexeo Therapeutics Chief Executive Officer Richard Nolan Townsend sold 55,000 shares on April 6, 2026, in a transaction totaling $313,137, according to an SEC Form 4. The sale, carried out under a Rule 10b5-1 plan adopted November 13, 2025, occurred as the company presented clinical data for AAV-based therapies LX2006 and LX2020 and announced senio…
Vir Biotechnology CEO Marianne De Backer sold 72,559 shares on April 6, 2026, through an automatic Rule 10b5-1 plan to satisfy tax obligations tied to restricted stock unit vesting. The trade, totaling about $664,350 at $9.156 per share, leaves her with substantial direct and indirect holdings. Separately, Vir completed a public offering that broug…
James Edgemond, Chief Financial Officer and Treasurer of United Therapeutics (NASDAQ: UTHR), sold 7,351 shares on April 6, 2026, for roughly $5.58 million and exercised options to buy 10,000 shares at $135.42. The trades come as the stock nears a 52-week high following positive Phase 3 TETON-1 results for Tyvaso and subsequent analyst target upgrad…
